AI国产自免双抗!进入2期临床

药融圈Stock Insight
Feb 11

注:本文不构成任何投资意见和建议,以官方/公司公告为准;本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及),不代表平台立场。任何文章转载需得到授权。药融圈监测显示:近期国家药品监督管理局批准了康方生物(9926.HK)自主研发的全球首个靶向IL-4Rα/ST2双特异性抗体AK139共7项适应症II期临床的开展,包括慢性阻塞性肺疾病、重度支气管哮喘、慢性自发性荨麻疹、过敏性鼻炎、慢性鼻窦炎伴...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10